Vaccinating Women Previously Exposed to Human Papillomavirus: A Cost-Effectiveness Analysis of the Bivalent Vaccine

Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States

(2013) Jane J. Kim   ANNALS OF INTERNAL MEDICINE

Male vaccination against human papillomavirus

(2012) David M Salisbury   LANCET INFECTIOUS DISEASES

End-of-study safety, immunogenicity and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

(2011) X Castellsagué et al.   BRITISH JOURNAL OF CANCER

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18

(2011) A. Szarewski et al.   INTERNATIONAL JOURNAL OF CANCER

Until Which Age Should Women Be Vaccinated Against HPV Infection? Recommendation Based on Cost-effectiveness Analyses

(2011) Tjalke A. Westra et al.   JOURNAL OF INFECTIOUS DISEASES

Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine

(2011) Aimée R. Kreimer et al.   JNCI-Journal of the National Cancer Institute

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Matti Lehtinen et al.   LANCET ONCOLOGY

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Cosette M Wheeler et al.   LANCET ONCOLOGY

The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands

(2011) Johannes A. Bogaards et al.   VACCINE

The current state of introduction of HPV vaccination into national immunisation schedules in Europe: Results of the VENICE 2008 survey

(2009) D. Lévy-Bruhl et al.   EUROPEAN JOURNAL OF CANCER

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom

(2009) Yoon Hong Choi et al.   VACCINE

Determinants for HPV vaccine uptake in the Netherlands: A multilevel study

(2009) Marc Rondy et al.   VACCINE

Age-Based Programs for Vaccination against HPV

(2009) Elamin H. Elbasha et al.   VALUE IN HEALTH

Health and Economic Implications of HPV Vaccination in the United States

(2008) Jane J. Kim et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model

(2008) Cara Usher et al.   VACCINE